About Impedimed
Impedimed is a company based in Carlsbad (United States) founded in 1999. Impedimed has raised $3.44 million across 8 funding rounds from investors including Versant Ventures and Starfish Ventures. The company has 77 employees as of June 30, 2025. Impedimed offers products and services including SOZO Digital Health Platform, L-Dex Analysis, and BodyComp Analysis. Impedimed operates in a competitive market with competitors including Bruker, Metrohm, Rigaku, Speclipse and Anvajo, among others.
- Headquarter Carlsbad, United States
- Employees 77 as on 30 Jun, 2025
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Impedimed Limited
-
Annual Revenue
$8.31 M (USD)23.31as on Jun 30, 2025
-
Net Profit
-$15.18 M (USD)-17.42as on Jun 30, 2025
-
EBITDA
-$12.82 M (USD)9.56as on Jun 30, 2025
-
Total Equity Funding
$3.44 M (USD)
in 8 rounds
-
Latest Funding Round
Not available
-
Investors
Versant Ventures
& 1 more
-
Employee Count
77
as on Jun 30, 2025
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Impedimed
Impedimed is a publicly listed company on the ASX with ticker symbol IPD in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Impedimed
Impedimed offers a comprehensive portfolio of products and services, including SOZO Digital Health Platform, L-Dex Analysis, and BodyComp Analysis.
Platform for bioimpedance spectroscopy to assess lymphedema early
Tool for monitoring lymphedema in cancer patients accurately
Analysis for segmental body composition in health assessments
People of Impedimed
Unlock access to complete
Unlock access to complete
Funding Insights of Impedimed
Impedimed has successfully raised a total of $3.44M across 8 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Impedimed
Impedimed has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Versant Ventures and Starfish Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Locked | Locked | Locked | |
|
Stage-agnostic sector-agnostic VC firm investing in Australia, New Zealand and the US
|
Locked | Locked | Locked |
Investor details for Impedimed
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Impedimed
Investment portfolio details for Impedimed
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Impedimed
Detailed financials for Impedimed
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Impedimed Comparisons
Peer comparison for Impedimed
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Impedimed
Impedimed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Bruker, Metrohm, Rigaku, Speclipse and Anvajo, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Diversified research instrument systems are manufactured and supplied.
|
|
| Locked | Locked | Locked |
Instruments for chemical analysis are developed and manufactured.
|
|
| Locked | Locked | Locked |
XRD, XRF, SAXS, Raman, metrology, and crystallography solutions are provided.
|
|
| Locked | Locked | Locked |
Molecular spectroscopy systems for early skin cancer detection are provided.
|
|
| Locked | Locked | Locked |
Point-of-care solutions for laboratory diagnostics are provided by Anvajo.
|
Detailed competitors of Impedimed
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Impedimed
Complete news archive for Impedimed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Impedimed
Impedimed was founded in 1999 and raised its 1st funding round 7 years after it was founded.
Impedimed is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
Rick Valencia is the current CEO of Impedimed.
Impedimed is a funded company, having raised a total of $3.44M across 8 funding rounds to date.
As of Jun 30, 2025, the latest employee count at Impedimed is 77.
Annual revenue of Impedimed is $8.31M as on Jun 30, 2025.
Impedimed was founded in 1999 and is headquartered in Carlsbad, United States. Non-invasive medical devices are developed by the company for clinical assessment and monitoring of fluid status. These devices support surgeons, oncologists, therapists, and radiation oncologists in evaluating patients for secondary lymphoedema. Operations focus on the health technology sector, with products designed for use in oncology and related therapeutic settings.
Impedimed offers SOZO Digital Health Platform, L-Dex Analysis, and BodyComp Analysis.
Yes, Impedimed is publicly traded on ASX under the ticker symbol IPD.
Impedimed has 2 investors. Key investors include Versant Ventures, and Starfish Ventures.
The ticker symbol of Impedimed is IPD on ASX.